It is known that Adriamycin, which is widely used in the treatment of various neoplastic conditions, exerts toxic effects in several organs. In this study, we have established that vitamin E has some beneficial effects on the kidney by protecting it from some of the toxcity induced by Adriamycin. A study was carried out which comprised one control group and two experimental groups of guinea pigs. In the experiment Adriamycin was administered either alone (group II) or together with vitamin E (group III). The results of groups II and III were compared with controls (group I). The kidneys were subsequently removed and examined by routine electron microscopic techniques. We found that vitamin E administered together with Adriamycin could reverse some of the degenerative changes caused by Adriamycin.

1.
Calendi E, Dimarco A, Reigiani M: On physicochemical interactions between daunomycin and nucleic acids. Biochim Biophys Acta 1965;103:25–49.
2.
Singal PK, Deally CMR, Weinberg LL: Subcellular effects of Adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817–828.
3.
Sinha BK, Politi PM: Anthracyclines Cancer Chemotherapy. Biol Resp 1990;11:45–57.
4.
Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Ojahlmann R, Lyons G, Kedes L, Toeti FM: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990;87:4275–4279.
5.
Mimnaugh EG, Trush MA, Gram TE: A possible role of membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem Pharmacol 1986;35:4327–4335.
6.
Yamamaka N, Kato T, Nishida K, Fujikawa M, Fukushima M, Ota K: Elevation of serum lipid peroxidase level associated with doxorubicin toxicity and its amelioration by di-alpha-tocopherol acetate or coenzyme Q 10 mouse. Cancer Chemother. Pharmacol 1979;223–227.
7.
Bier JQ; Corash L; Hubbard VS: Medical uses of vitamin E. N Engl J Med 1983;308:1063–1071.
8.
Doroshow JT: Anthracycline antibiotic stimulated superoxide, hydrogen peroxide and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983;43:4543–4551.
9.
Wang YM, Madonat FF, Kimball JC, Glesier CA, Ali MK, Kaufman MW, Van Eys J: Effects of vitamin E against Adriamycin-induced toxicity in rabbits. Cancer Res 1980;40:1022–1027.
10.
Uchiyama M, Mihara M: Determination of MDA precursor in tissue by thiobarbituric acid test. Anal Biochem 1987;86:271–278.
11.
Bender RA, Zwelling LA, Doroshow JH, Locher GY, Hande KR, Murinson DS, Cohen M, Myers C, Chabner BA: Antineoplastic drugs: Clinical pharmacology and therapeutic use. Drugs 1978;16:46.
12.
Blum RH: An overview of studies with Adriamycin (NSC123127) in the United States. Cancer Chemother Rep 1975;6:247.
13.
Bertelli R, Ginevzi F, Gusmamo R, Ghiggeri GM: Cytotoxic effect of Adriamycin and agarose-coupled Adriamycin on glomerular epithelial cell: Role of free radicals (abstract). In Vitro Cell Dev Biol 1991;27:799–804.
14.
Bertani T, Cutillo F: Tubulo-interstitial lesions mediate renal damage in Adriamycin glomerulopathy. Kidney Int 1986;30:488–496.
15.
Bertani T, Poggi A, Pozzani R, Delanini F, Sacchi IG, Thoua Y, Mecca G, Remuzzi G, Donati MB: Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982;46:16–23.
16.
Giroux L, Smeesters C, Bury F, Faure MP, Jean G: Adriamycin and Adriamycin-DNA nephrotoxicity in rats. Lab Invest 1984;50:190–196.
17.
Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishma M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986;29:502–510.
18.
Fajarda LF, Eltringhom JR, Stewart JR, Klauber MR: Adriamycin nephrotoxicity. Lab Invest 1980;43:242–253.
19.
Strenberg SS, Philips FS, Cronin AP: Renal tumors and other lesions in rats following a single intravenous injection of daunomycin. Cancer Res 1972;32:1029–1036.
20.
Okasora T, Takikawa T, Utsunomiya Y, Senoh J, Hayashibara H, Shiraki K, Shihiru I: Suppresisi and effect of superoxide dismutase on Adriamycin nephropathy. Nephron 1992;60:199–203.
21.
Tulio B, et al: ADR-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982;46:16–23.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.